Kornimate/medical-research-clean huggingface dataset:
impact of cpap level on v/q mismatch in premature infants

Conditions: Infant, Premature, Diseases; Respiratory Insufficiency Syndrome of Newborn

Summary: continuous positive airway pressure (cpap) is used in premature infants to maintain lungs open and facilitate gas exchange. when ventilation/perfusion (v/q) mismatch is present, areas of the lung that are open for gas exchange do not match up with the areas of the lung that are receiving blood for gas exchange. this study measure the responsiveness of v/q mismatch to changes in the amount (or level) of cpap.


Eligibility criteria:
inclusion criteria: 1. born at 27-35 weeks gestational age (ga) by best obstetric estimate, determined by the clinical obstetric team during antepartum admission. 2. age limits: 24 hours of age - 35 weeks corrected gestational age. 3. on continuous cpap support between 4-8 cm h2o for greater than 24 hours, as document on the bedside infant flow sheet. 4. supplemental oxygen requirement, with a fraction of inspired oxygen (fio2) 0.25 for at least 2 consecutive hours, as documented on the bedside infant flow sheet. exclusion criteria: 1. congenital anomalies, as determined by the clinical supervising physician. 2. current or prior air leak syndrome, as determined by the clinical supervising physician.

Keywords: cpap bronchopulmonary dysplasia ventilator induced lung injury v/q mismatch
identification of genetic determinants for treatment resistance/sensitivity and/or toxicity in adjuvant setting for her2 positive breast cancer

Conditions: HER2-positive Breast Cancer

Summary: this is a multicenter, non-randomized, prospective cohort study. the purpose of the study is to identify constitutional genetic factors associated with histological response, resistance or sensibility to treatment in human epidermal growth factor receptor 2 (her2)-positive breast cancer. 9000 patients will be enrolled in this study. blood samples will be collected after informed consent and inclusion in the study. patients will be treated and followed according to the standards of their treating center. they will be followed every six months for five years.

the purpose of the sigher trial is to create a cohort of 9000 patients with her2-positive breast cancer including detailed epidemiologic and treatment data. the distribution of constitutional genetic variants will be evaluated within groups of patients treated with different regimes of targeted therapies, identifying variants associated with histological response, as well as sensitivity or resistance to these therapies. blood samples will be collected in two 6ml ethylenediaminetetraacetic acid (edta) tubes after informed consent and inclusion in the study. as the samples are received at the biological resource center, total blood will be aliquoted into a 500 µl tube and frozen at -80° c. dna will be extracted using standard protocols. dna will be stored in anticipation of genetic analyses. an aliquot of the dna sample will be genotyped for a panel of high-density genetic markers covering the whole genome for genome-wide association studies.

Eligibility criteria:
for inclusion in the study, patients must be affiliated to the national or local social security, and must meet all the following criteria: inclusion criteria: * age ≥ 18 years * histological diagnosis of breast adenocarcinoma. non-metastatic and operable. * current or prior treatment with one therapy targeting her2 in adjuvant or neoadjuvant phase for the current breast cancer * given written informed consent exclusion criteria: * patients not able to comply to the protocol assessments for geographic, social or psychological reasons * patients placed under judicial protection, guardianship, or supervision * history of cancer in the 5 years preceding anti-her2 therapy initiation * concomitant cancer (except for an other non metastatic cancer treated only with surgery) note : patients are eligible at any time of the follow-up if the adjuvant or neoadjuvant chemotherapy started after 01/01/2019. patients treated with trastuzumab, pertuzumab, neratinib or t-dm1 in a clinical trial are eligible in the sigher study.
a preliminary study about unexplained recurrent miscarriage and repeated implantation failure patients treated with low-dose lymphocyte immunotherapy

Conditions: Unexplained Recurrent Miscarriage and Recurrent Implantation Failure

Summary: recurrent miscarriage(rm) and recurrent implantation failure (rif) are clinical challenge for clinicians and patients who are desperate for a healthy child.the specific etiology contains chromosomal abnormalities, reproductive anatomical abnormalities, endocrine disorders, reproductive system infections, autoimmune and environmental factors. however there are still 50% to 60% rm and rif which don't have a clear cause,mainly associated with alloimmune factors.among various treatments,lymphocytes active immunotherapy is the most common treatment method, and its clinical efficacy is widely recognized although its action mechanism is not clear so far.

the main mechanism of active immunotherapy includes upregulating th2-type cytokines, downregulating th1-type cytokines, making th1 / th2 shift to th2, inducing maternal serum il-6 and sil6r, pibf, egf; inducing the expression of fas / fasl on lymphocyte surface; increasing the proportion of cd8 + cells, th2-type cells and cd + cd25 + treg cells, decreasing the activity of cd56 + cd16 + nk cell and so on.the purpose of this study is to observe the treatment effects of active immunotherapy on urm and rif patients. what's more,we will used flow cytometry, and quantitative real-time pcr (qpcr) methods to characterize th1、th2 and treg cell populations after immunotherapy,ecpecting to find out the exact molecule mechanism of immunotherapy with paternal or third party lymphocytes.

Eligibility criteria:
inclusion criteria: * healthy except for their history of recurrent abortions and were negative for blocking antibodies * willing to receive follow up exclusion criteria: * patients with genetic impairment * patients with mullerian anomaly * patients with hormonal deficiency * patients with metabolic disorder * patients with infectious disease * patients with autoimmune abnormalities

Keywords: urm rif th1 th2 treg lymphocyte immunotherapy
phosphatidylcholine (lt-02) for induction of remission in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to compare two different dosing regimens of phosphatidylcholine versus placebo for the induction of remission in ulcerative colitis patients non-responsive to standard mesalamine treatment.


Eligibility criteria:
inclusion criteria: * established diagnosis of ulcerative colitis * active ulcerative colitis disease extent ≥ 15 cm * active disease despite treatment with mesalamine exclusion criteria: * crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, microscopic colitis, diverticular disease associated colitis, * toxic megacolon or fulminant colitis * colon resection * evidence of infectious colitis * celiac disease * bleeding hemorrhoids * history or presence of ischemic heart disease, myocardial infarction, peripheral arterial disease, ischemic stroke, or transient ischemic attack * any severe concomitant renal, endocrine, or psychiatric disorder * any relevant known systemic disease * history of cancer in the last five years * abnormal hepatic function or liver cirrhosis * abnormal hba1c at screening visit * patients with known hypersensitivity to soy * known intolerance/hypersensitivity to investigational medicinal product (imp) * treatment with steroids/methotrexate/tumor necrosis factor-alpha-antagonists/azathioprine/ 6-mercaptopurine/anti-integrin/coumarins * treatment with other investigational drug * existing or intended pregnancy or breast-feeding
lip-01 in hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to determine a safe and tolerable dose of lip-01


Eligibility criteria:
inclusion criteria: * age between 18-75 years * plasma total-cholesterol \>5.2 mmol/l (\> 200 mg/dl) * willingness to adhere to the requirements of the protocol, including availability for follow-up visits and donation of blood samples * willingness and ability to sign written informed consent * women of child bearing capacity who agree to use an acceptable form of birth control during the trial \[i.e., oral contraception, reliable use of a double-barrier method (e.g., condom and diaphragm, condom and foam, condom and sponge), iud or tubal ligation\] exclusion criteria: * plasma triglycerides \> 4.0 mmol/l (\> 354 mg/dl) * plasma ldl ≥ 5.0 mmol/l (≥ 195 mg/dl) * current coronary artery/ cardiovascular disease or history of a cardiovascular event (stroke, transient ischemic attack, myocardial infarction, angioplasty or coronary artery bypass grafting, angina pectoris) * moderate/high risk of coronary artery/ cardiovascular disease * diabetes mellitus * uncorrected hypothyroidism * other significant metabolic endocrine disease * uncontrolled hypertension (\>160 systolic or \>100 diastolic) * active liver disease (alt \>2x normal) * significant gastrointestinal disease * acute inflammatory disease * significant kidney disease (calculated by egfr \<60 ml/min) * any other significant medical condition which, in the opinion of the investigator, could compromise patient safety or confound trial results * any significant/relevant surgery within the last year * use of lipid-lowering drugs * treatment within the previous 6 months with any medication that is known to affect lipid or lipoprotein levels (such as statins, fibric acid derivatives, bile acid sequestrants, ezetimibe, nicotinic acid) * regular use of natural health products or dietary supplements known to affect lipid or lipoprotein levels (omega-3 fatty acids, green tea extracts, guggulipid, psyllium, plant sterols, policosanols). if the participants agree to stop taking these products prior to study entry and for the duration of the study, they can participate in the study. * pregnant or lactating women * known allergy to any ingredient in the study product, including: coptis chinensis, ilex kudingcha, microcrystalline cellulose and magnesium stearate
distances from cricoid cartilage to the targets of stellate ganglion block

Conditions: Herpes Zoster; CRPS

Summary: stellate ganglion block targets are c6 transverse process or c7 transverse process in anterior paratracheal approach which is most popular method. cricoid cartilage is known that it is located at c6 level in supine neutral position of the neck. but stellate ganglion block is performed in supine extended position of the neck. so cricoid cartilage will move up to cephalad direction and pain doctors should find c6 or c7 transverse process at lower neck area than cricoid cartilage.


Eligibility criteria:
inclusion criteria: * adults above age of 20 reserved for musculoskeletal ultrasonography exclusion criteria: 1. past history of neck surgery 2. the limitation of neck motion due to rheumatoid arthritis, et al. 3. severe neck pain 4. inability to communicate or read or write
observational study of early contact with palliative care unit for patients receiving first line palliative chemotherapy with cancer in upper gastrointestinal canal, or second line palliative chemotherapy in patients with colorectal cancer - an open, randomised investigator initiated trial.

Conditions: Tumor in Upper Gastrointestinal Canal or Patients With Colorectal Cancer

Summary: in this trial, patients with cancer in the upper gastrointestinal canal who are going to receive first line palliative chemotherapy and patients with colorectal cancer who are going to receive second line palliative chemotherapy will be included. participating patients will be randomized between early contact with a palliative care unit, or contact with a palliative care unit when needed. the objectives with the trial is to investigate if an early establishment with a palliative care unit will have a positive impact on the patients quality of life, this also applies for the nearest relative, survival, and if a difference in numbers of chemotherapy cycles can be detected.


Eligibility criteria:
inclusion criteria: * patients with tumor in upper gastrointestinal canal, who is going to start treatment with first line palliative chemotherapy * patients with colorectal cancer, who is going to start treatment with second line palliative chemotherapy * signed written informed concent exclusion criteria: * patients with neuroendocrine tumor * patients with already ongoing chemotherapy * patients with already established contact with palliative care unit

Keywords: colorectal neoplasms depression intestinal neoplasms gastrointestinal neoplasms digestive system neoplasms digestive system diseases gastrointestinal diseases intestinal diseases palliative chemotherapy palliative care palliative treatment quality of life quality of life for relatives survival
prognostic value of aβ imaging in nph prior to shunt placement

Conditions: Normal Pressure Hydrocephalus Patients

Summary: in this pilot study the investigators shall prospectively in a blinded fashion evaluate with aβ pet in patients committed to shunt surgery and then investigate the relationship of these biomarkers with outcome on gait, cognition and urinary control improvement in the short term (3 months) and long term (1 year). the imaging agent will be provided by avid. furthermore the study will standardize imaging studies using florbetapir f 18 pet to provide information on amyloid burden.


Eligibility criteria:
inclusion criteria: 1. age ≥ 60. 2. visual and auditory acuity adequate for neuropsychological testing. 3. completed six grades of education or has a good work history (sufficient to exclude mental retardation). 4. must speak english fluently. 5. willing to undergo one amyloid imaging pet scan. 6. agrees to at least one lumbar puncture for the collection of csf. 7. must agree to return for a month 3 and month 12 visit. 8. participant, who in the opinion of the investigator, can tolerate the pet scan procedures exclusion criteria: 1. history of schizophrenia (dsm iv criteria). 2. history of alcohol or substance abuse or dependence within the past 2 years (dsm iv criteria). 3. participation in clinical studies involving neuropsychological measures being collected more than one time per year. 4. exclusion for amyloid imaging with 18f -av-45: current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the participant in any given year would exceed the limits of annual and total dose commitment set forth in the us code of federal regulations (cfr) title 21 section 361.1. 5. clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances as indicated by history, which in the opinion of the investigator might pose a potential safety risk to the participant? 6. current clinically significant cardiovascular disease, including one or more of: * cardiac surgery or myocardial infarction within the last 4 weeks; * unstable angina; * acute decompensated congestive heart failure or class iv heart failure
effect of autologous platelet-rich plasma in uterine wound healing

Conditions: Cesarean Section Complications

Summary: the aim of this study is to evaluate the efficacy of intramuscular autologus platelet rich plasma on uterine wound healing after primary cesarean section

110 pregnant female undergoing primary prelabor cs will be randomized to two groups group a)autologus prp will be prepared from participant venous blood collected from the participants' arm into a syringe primed with acd-a. then it will be injected into uterus after closing uterine incision . injection sites will be selected near the incision at evenly 20 different sites group b)normal saline 0.9 will be injected into uterus after closing uterine incision . injection sites will be selected near the incision at evenly 20 different sites.

Eligibility criteria:
inclusion criteria: * term pregnancy (gestational age between 37-41 weeks). * women undergoing cesarean section for the first time. * normal vaginal ultrasound examination and exclusion of any pelvic abnormality. * uncomplicated cesarean section. * lower uterine segment cesarean sections while the women not in labor exclusion criteria: * women with complications during or after cesarean section as intrapartum or postpartum hemorrhage, puerperal sepsis, septic wound * women with medical diseases that can affect the healing as diabetes mellitus, anemia, chronic renal disease or hepatic disease or coagulopathy or receiving medications affect wound healing as corticosteroids or anticoagulant. * women who will use intrauterine device as a contraceptive method women with uterine abnormality as cervical stenosis or fibroid uterus multiple gestation, placenta abruption, placenta previa, antepartum hemorrhage prolonged rom, chorioamnionitis,meconium stained liquor
syrenity app for depression

Conditions: Depressive Symptoms

Summary: the goal of this clinical trial is to learn if the syrenity mental health app reduces depressive symptoms when compared to a control condition. secondarily, the trial will provide data on the usability and acceptability of the syrenity app. the main questions it aims to answer are: does syrenity reduce self-reported depressive symptoms compared to a waiting list control? how usable is the syrenity app?


Eligibility criteria:
inclusion criteria: * phq-9 \>= 10 * use an iphone or android * residing in the united states exclusion criteria: * phq-9 item 9 \>= 2
zirconia implants: practice-based evidence

Conditions: Dental Implants; Ceramic Implant

Summary: this study is a prospective case series clinical study to examine the effectiveness of ceramic dental implants manufactured by swiss dental solutions (sds). participants with an indication from the dentist for teeth extraction and replacement are invited to participate in this study. participating in this study will involve the use of dental implants manufactured by swiss dental solutions (sds zirconia dental implants), submission of the case data, including pre-operative information, intra-operative details, and post-operative follow-up data, to the study site and its collaborating partners. the sds zirconia dental implants used in this research are fda cleared devices that are available for dental treatments.

to evaluate the effectiveness of one-piece ceramic implants placed into fresh extraction sockets and provide practical clinical evidence, the investigators will assess their performance in defined clinical settings, encompassing a variety of clinical situations, patients, and practitioners. this evaluation, conducted according to a precise surgical and treatment protocol, considers factors such as patient and clinician variability and long-term outcomes in routine clinical practice. study question: the cumulative survival rate (csr), marginal bone level (mbl) and pink esthetic score (pes) of one-piece ceramic implants supporting crowns during a 12-month follow-up period will be determined.

Eligibility criteria:
inclusion criteria: * the need for implant placement in position of single or multiple teeth to be extracted and to replace up to 3 teeth * availability of patient for a minimum follow-up of one year following implantation * availability of complete follow-up data in medical records * availability of post-operative and follow-up periapical radiographs exclusion criteria: * history of head and neck irradiation * history of bisphosphonate or medications that induce osteonecrosis of the jaw * untreated systemic diseases that are known to affect wound healing, such as uncontrolled diabetes mellitus * immunocompromised or immunoproliferative diseases * heavy smoking of \&gt;10 cigarettes per day

Keywords: ceramic implants titanium implants peri-implantitis marginal bone loss soft tissue bone augmentation immediate implantation dental implants immediate loading
mollii - personalized suit for treatment of spasticity, gfmcs 3-5

Conditions: Spastic Cerebral Palsy

Summary: the objective of this study was to examine the effect on spasticity and function of multifocal transcutaneous electrical stimulation incorporated in a 2-piece (mollii) suit.

in this prospective cohort study, the participants (children with predominantly spastic cp, gfmcs 3-5) wore the suit for 1 hour every second day for 24 weeks. the investigators evaluated level of spasticity using the modified ashworth scale (mas) and other related measures before initiation, after 4, 12, and 24 weeks. two motor related smart goals were defined and evaluated by the goal attainment scale (gas). gmfm-66 and posture and postural ability scale (ppas) were performed.

Eligibility criteria:
inclusion criteria: - cerebral palsy with spastic disease, gmfcs 3-5. exclusion criteria: * other disorders affecting the sensorimotor functions without spasticity, * implanted electric medical devices, * bmi\>35 * other severe concomitant diseases such as cancer, cardiovascular, inflammatory, psychiatric disease, medical dysregulated epilepsy or hypertension.

Keywords: mollii suit; goal attainment scale; reciprocal inhibition; modified ashworth scale, trans cutaneous electric stimulation, tens spasticity reduction,
comparison of methacholine bronchial provocation with wright and devilbiss646 nebulizers

Conditions: Asthma

Summary: the purpose of this study is to compare the diagnostic validity (sensitivity and specificity) and evaluate the safety of 2-min tidal breathing methacholine bronchial provocation tests with the wright and devilbiss646 nebulizers in asthmatic in guangzhou.

after screening,each asthmatic patient will visit the investigators' center 4 times. during the first week, the patient will be randomised to undergo methacholine bronchial challenge with wright or devilbiss 646 nebulizer on two separate days, which are at least 24 hours but not more than 7 days apart.the above procedure will be repeated for each patient in one month. but the nebulizer will be selected in a reverse order.provocative concentration induced a 20% decrease in forced expiratory volume in one second (pc20) will be calculated for each test. record all the adverse events during the tests.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of asthma; * stable for more than 4 weeks with fev1≥65%pred exclusion criteria: * exacerbation within 3 months; * upper airway infections within 4 weeks; * concomitant of hypertension or heart diseases; * pregnancy; * under immunotherapy